Barriers and facilitators to detoxification from opioid substitution treatment: A mixed‐methods systematic review

BACKGROUND AND AIMS: Despite the well-documented benefits of opioid substitution treatment (OST) in treating opioid dependence (OD), many people diagnosed with OD desire to live a drug-free life. The transition to abstinence involves detoxification: a gradual dose reduction of OST to zero milligrams. Despite these aspirations, only a minority of patients undertake detoxification, and successful completion remains limited. This mixed-methods systematic review aimed to identify the barriers and facilitators to detoxification from OST, to help provide a better understanding of what can be done to support patients and improve outcomes in OD. METHODS: Four databases were searched until 22 January 2025: PubMed, Embase, APA PsycINFO and CINAHL. Qualitative, quantitative and mixed methods studies of individuals with a diagnosis of OD undergoing detoxification from OST, or staff responsible for providing the treatment, were included. Studies of only pharmacological interventions were excluded. An integrated approach to data synthesis was used, transforming quantitative data into textual descriptions to integrate them with qualitative data and form one set of themes. Joanna Briggs Institute checklists were used to assess the quality of included papers. RESULTS: From 1999 studies identified, 41 papers were deemed eligible. Studies originated from the USA (22), UK (7), Sweden (6), Canada (1), Ireland (1), Norway (1), Switzerland (1), Australia (1) and China (1). The medications explored included methadone (28), buprenorphine (5), both forms (6) and unspecified OST (2). Studies were conducted in outpatient settings (29), inpatient settings (7), mixed settings (4) and a prison setting (1). Participants included patients (37), treatment providers (1) and mixed populations (3). Factors affecting detoxification were present at an individual and structural level, with overlap between influences at the initiation and completion phases. Eight themes emerged, comprising psychological and emotional factors (particularly around fear of detoxification), personal motivation, withdrawal symptoms, clinical and demographic factors, environmental factors, social factors, professional support and treatment models/interventions. 54% of included studies were rated high quality, and 37% of medium quality. CONCLUSION: Detoxification from opioid substitution treatment appears to be commonly hindered by fear, emotional resurgence, low confidence, environmental turbulence, negative social influences and insufficient professional/pharmacological support, while facilitators include psychological readiness, life stability, supportive relationships, psychological interventions, inpatient facilities and adjunctive medications.

Authors

Institutions

Publication Details

Journal
Addiction
Published
2026-06-17
DOI
https://doi.org/10.1111/add.70482
Primary Topic
Opioid Use Disorder Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Barriers and facilitators to detoxification from opioid substitution treatment: A mixed‐methods systematic review

India Olchefske, Louise M. Paterson, Anne Lingford‐Hughes, Suleyman Shah et al.
Addiction
Opioid Use Disorder Treatment
article

Barriers and facilitators to detoxification from opioid substitution treatment: A mixed‐methods systematic review

India Olchefske, Louise M. Paterson, Anne Lingford‐Hughes, Suleyman Shah, Amy Bagshaw, Mike J Crawford
article en

Abstract

BACKGROUND AND AIMS: Despite the well-documented benefits of opioid substitution treatment (OST) in treating opioid dependence (OD), many people diagnosed with OD desire to live a drug-free life. The transition to abstinence involves detoxification: a gradual dose reduction of OST to zero milligrams. Despite these aspirations, only a minority of patients undertake detoxification, and successful completion remains limited. This mixed-methods systematic review aimed to identify the barriers and facilitators to detoxification from OST, to help provide a better understanding of what can be done to support patients and improve outcomes in OD. METHODS: Four databases were searched until 22 January 2025: PubMed, Embase, APA PsycINFO and CINAHL. Qualitative, quantitative and mixed methods studies of individuals with a diagnosis of OD undergoing detoxification from OST, or staff responsible for providing the treatment, were included. Studies of only pharmacological interventions were excluded. An integrated approach to data synthesis was used, transforming quantitative data into textual descriptions to integrate them with qualitative data and form one set of themes. Joanna Briggs Institute checklists were used to assess the quality of included papers. RESULTS: From 1999 studies identified, 41 papers were deemed eligible. Studies originated from the USA (22), UK (7), Sweden (6), Canada (1), Ireland (1), Norway (1), Switzerland (1), Australia (1) and China (1). The medications explored included methadone (28), buprenorphine (5), both forms (6) and unspecified OST (2). Studies were conducted in outpatient settings (29), inpatient settings (7), mixed settings (4) and a prison setting (1). Participants included patients (37), treatment providers (1) and mixed populations (3). Factors affecting detoxification were present at an individual and structural level, with overlap between influences at the initiation and completion phases. Eight themes emerged, comprising psychological and emotional factors (particularly around fear of detoxification), personal motivation, withdrawal symptoms, clinical and demographic factors, environmental factors, social factors, professional support and treatment models/interventions. 54% of included studies were rated high quality, and 37% of medium quality. CONCLUSION: Detoxification from opioid substitution treatment appears to be commonly hindered by fear, emotional resurgence, low confidence, environmental turbulence, negative social influences and insufficient professional/pharmacological support, while facilitators include psychological readiness, life stability, supportive relationships, psychological interventions, inpatient facilities and adjunctive medications.

Addiction
Imperial College London (GB)
Medical Research Council, Economic and Social Research Council
Openalex Percentile: Top 6%
Opioid Use Disorder Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.